The Silicon Review
Sintetica is at the heart of innovation that is transforming the pharmaceutical industry. Established in 1921 in Switzerland, Sintetica provides injectable anesthetics and analgesics to patients worldwide through innovative science and excellence in development, production, and marketing.
Built to support both the robust national growth and the rapid global expansion, the company has an agile and multicultural high-performing corporate structure.
With 300 employees from 29 different countries in the world, Sintetica has got offices located in Switzerland, Germany, Austria, Italy and United Kingdom. Headquartered in Mendrisio, Switzerland, the innovation department employees 15% of the Sintetica’s total workforce. Also, the Swiss manufacturing sites of Mendrisio and Couvet have a production capacity of 60 million ampoules, 5 million infusion bags, and over 5 million vials.
The Swiss Leader of Pharmaceutics
Over the years, the company has gained immense popularity in the pharmaceutical industry. Fully committed to innovating therapies and drugs in local anesthesia and pain management, Sintetica has been the market leader for many years. Driven by the jet-speed growth, the company is now moving towards developing a leadership position in the growing field of neuromodulation.
After years’ of hardship, in 2012 the company established a global division, which was the first international corporate structure which was tasked with pursuing international growth under a B2B licensing strategy and somewhat later a B2C strategy in select markets.
Today, with more than 350 product registrations in over 100 different countries, Sintetica has built a huge network of partners. Constantly focusing on high-speed robust partner selection and affiliation in every country of the world, the Global division is determined to offer a dynamic portfolio of selected branded medicines, developed to answer unmet clinical needs, to build sustainable and long-lasting alliances.
The first phase of expansion covered North, Central and South America, South East Asia, and the Pacific. Many of these registrations have yet to come through, but so far the company has seen strong growth in the US, and some good returns in the Pacific.
“To achieve this leadership by innovation in the context of global growth, we consider strategic partnering and business development the key factors.”
The Corporate Culture
“Respect is the core value of a company and it permeates across every employee”, and for Sintetica, its people are the biggest asset of the company. For the Switzerland-based firm, the concept of respect is divided into well-defined directions, which is expressed in relation to its employees, enhancing different characteristics. And the same concept is also expressed towards the patients using Sintetica drugs worldwide, providing them with the highest quality products and investing in innovation to imagine the best care solutions for the future. Everyone at Sintetica works seriously and takes the responsibility and obligation to meet the highest standards of business ethics and integrity. That is why, when hiring new employees, the company look for ‘smart’ people who share the same vision like the company.
“We look for people who share our thirst for diversity, our respect for traditions and our aim to be a global leading company.”
The Interview Snippet with Augusto Mitidieri, CEO of Sintetica
How does it feel to have been selected in the 30 Most Reputable companies of the year - 2018?
It’s a deep joy and it represents a reward for the big efforts and a strong ambition to move Sintetica from a small Swiss excellence to a leading global company. This award makes me and all 300 employees of Sintetica proud and honored for the incredible work done. And as the Corporate CEO, I have complete responsibility for all the sites and affiliates of the company, and I see my role as defining the strategy and vision of the organization.
I believe in a company culture that promotes creativity and informed risk-taking. In this respect, it must also promote a good feeling for all employees and should always feel safe when they are at work. Making Sintetica a great place to work has always been my top priority; something that is very much of a part of the company DNA. I consider our people to be the company’s core resource and that is why I trust those who work in my organization, who are open to change and drive the innovation.
What does the future hold for SINTETICA?
Hopefully a lot of good news and strong returns to my team’s great efforts!
We recently obtained Marketing Authorization in the US for a New Drug Application, Clorotekal (spinal Chloroprocaine), which is an outstanding achievement. In fact, we are one of the few small medium-sized companies in the world that actually managed to register an original “innovative” product in the United States.
With a network of partners who share our ‘quality first’ value, we should be able to maintain and expand our current innovation-driven value proposition significantly over the next five years.
Moreover, one radical innovation in the field of pain relief after surgery is in the final stages of development. The potential of this innovation could be disruptive all over the world and could enhance the way pain is managed in hospital and at home after surgery.